Exponent (EXPO) CFO receives incentive and non-qualified stock option grants

Rhea-AI Filing Summary

SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.

Exponent Inc EVP & CFO Richard L. Schlenker Jr. reported awards of stock options on February 20, 2026. He received 1,425 incentive stock options and 17,575 non-qualified stock options, each representing rights to buy Exponent shares. According to the footnotes, these options become exercisable in four equal annual installments.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider SCHLENKER RICHARD L JR

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	1,425	$0.00	--
Grant/Award	Non-Qualified Stock Option (right to buy)	17,575	$0.00	--

Holdings After Transaction: Incentive Stock Option (right to buy) — 1,425 shares (Direct); Non-Qualified Stock Option (right to buy) — 17,575 shares (Direct)

Footnotes (1)

1. The stock option becomes exercisable in four equal annual installments. Not applicable.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHLENKER RICHARD L JR

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	$70.16	02/20/2026		A		1,425		(1)	02/20/2036	Common Stock	1,425	(2)	1,425	D
Non-Qualified Stock Option (right to buy)	$70.16	02/20/2026		A		17,575		(1)	02/20/2036	Common Stock	17,575	(2)	17,575	D

Explanation of Responses:

1. The stock option becomes exercisable in four equal annual installments.

2. Not applicable.

	By: Wendy Whitehouse For: Richard L. Schlenker, Jr.	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Exponent (EXPO) report for Richard L. Schlenker Jr.?

Exponent reported that EVP & CFO Richard L. Schlenker Jr. received two stock option grants. He was awarded 1,425 incentive stock options and 17,575 non-qualified stock options, each representing rights to buy Exponent common shares, vesting over four equal annual installments.

Were the Exponent (EXPO) option grants to Richard L. Schlenker Jr. open-market purchases?

No, the transactions were classified as option grants, not open-market purchases. They are reported with code “A” for grant or award acquisition and a price per share of 0.0000, indicating compensatory awards rather than cash purchases in the market.

How many Exponent (EXPO) stock options were granted to the CFO on February 20, 2026?

On February 20, 2026, the CFO received 1,425 incentive stock options and 17,575 non-qualified stock options. These awards are reported as derivative securities, each representing rights to acquire Exponent common stock upon exercise, subject to the stated vesting schedule.

What is the vesting schedule for the Exponent (EXPO) options granted to the CFO?

The filing states that the stock options become exercisable in four equal annual installments. This means each grant vests over four years, with one-quarter of the options becoming exercisable each year, aligning compensation with longer-term service at Exponent.

Does the Exponent (EXPO) Form 4 show any insider sales by the CFO?

The Form 4 shows only acquisition-type transactions classified as grants or awards. There are no reported sales or dispositions, and the transaction summary lists acquireCount as 2 with sellCount and disposeCount both at zero for this reporting period.